Technical Data Sheet

InVivoMAb anti-human GPC-2

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**BE0402**
Clone:	**CT3**
Isotype:	Mouse IgG1, κ
Recommended Isotype Control(s):	InVivoMAb mouse IgG1 isotype control, unknown specificity
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Reported Applications:	Immunohistochemistry (paraffin) Flow cytometry ELISA Western blot
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤1EU/mg (≤0.001EU/µg) Determined by LAL gel clotting assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 µm filtered
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein G
RRID:	
Molecular Weight:	150 kDa

Description

The CT3 monoclonal antibody reacts with tumor-associated exons 3 and 10 of glypicans-2 (GPC2), a cell surface glycoprotein differentially expressed in neuroblastomas compared with normal tissues. GPC2 is also known as cerebroglycan, and it is one of the six members of glypicans, which are glycosylphosphatidylinositol (GPI)-anchored cell surface coreceptors. GPCs interact with multiple growth factors and chemokines to regulate the processes of cell proliferation, death, and differentiation. N-myc proto-oncogene protein (MYCN) controls the expression of GPC2 at its transcriptional level. Enhanced GPC2 expression in neuroblastoma promotes the Wnt/β-catenin pathway and upregulates N-Myc expression to drive tumorigenesis. Among various GPC2 antibodies, the CT3 antibody is known to recognize over-expressed GPC2 in neuroblastoma, and it does not show reactivity in normal peripheral nerves or other normal tissues. The CT3 antibody does not bind to any other GPCs. CT3-based CAR T cells directed towards GPC2 show potent anti-tumor activity in vivo in preclinical mouse models of localized as well as metastatic neuroblastoma. GPC2 antibody-drug conjugates (e.g., D3-GPC2-PBD) have been documented to deliver cytotoxicity in neuroblastoma cell lines and robust antitumor effects in human neuroblastoma patient-derived xenograft (PDX) in vivo models.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out

of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/be0402?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC